Roche Acquires Inflazome for €380 Million Upfront, Gaining Full Rights to Its NLRP3 Inhibitor Portfolio

YiOu Health reported on the 21st,InflazomeAnnounced that a share purchase agreement has been reached with Roche; Inflazome’s shareholders will receive an upfront payment of €380 million and will be eligible for additional milestone payments.

Inflazome, a biotechnology company headquartered in Dublin, Ireland, was founded in 2016 by medical researchers Matt Cooper (University of Queensland, Australia) and Luke O’Neill (Trinity College Dublin, Ireland). The company is dedicated to the development of novel therapeutics targeting the inflammasome. Previously, Inflazome secured €55 million in funding from investors including Forbion, Longitude Capital, Fountain Healthcare Partners, and the Novartis Venture Fund.

Currently, Inflazome’s portfolio consists of clinical and preclinical oral small moleculesNLRP3 InhibitorsComposition: The lead compound has successfully completed Phase I clinical trials. It is reported that the activated NLRP3 inflammasome, acting as a "danger sensor" in vivo, is associated with variousChronic Inflammatory Diseasesincluding Parkinson's disease, Alzheimer's disease, asthma, chronic kidney disease, cardiovascular disease, arthritis, and non-alcoholic steatohepatitis (NASH).

Through thisAcquisitionRoche will hold full rights to Inflazome’s entire product portfolio, with plans to further develop NLRP3 inhibitors across various indications characterized by high unmet medical needs.

This article is sourced from Yiou, an original piece by author Lin Yiling. For reprinting or collaboration, please click here.Reprint Notice, Unauthorized reproduction will be subject to legal action.